Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society

Download as PDF

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the Jefferies 2019 Global Healthcare Conference and the JMP Securities Life Sciences Conference. In addition, Imeglimin will be discussed during a symposium at the 62nd Annual Meeting of the Japanese Diabetes Society.

  • The 62nd Annual Meeting of the Japanese Diabetes Society is being held on May 23-25, 2019 at the Sendai International Center, Sendai, Japan. Imeglimin will be discussed in Featured Symposium #4 on New Mode of Action Drugs to Clinical on Thursday, May 23rd, 2019 from 2:30-5:00 PM JST.
  • The Jefferies 2019 Global Healthcare Conference is being held on June 4-7, 2019 at The Grand Hyatt Hotel in New York City. The Company will present a corporate overview on Wednesday, June 5th from 10:30-10:55 AM EDT and will be available to participate in one-on-one meetings with investors. The presentation will be webcast live. To access the webcast, please visit the following link http://wsw.com/webcast/jeff118/poxel.pa/. The webcast replay will remain available for 90 days following the live presentation.
  • The JMP Securities Healthcare Conference is being held on June 19-20, 2019 at the St. Regis Hotel in New York City. The Company will present a corporate overview on Wednesday, June 19th from 11:30-11:55 AM EDT and will be available to participate in one-on-one meetings with investors.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985

Investor relations / Media - EU/US
Trophic Communications
Stephanie May or Joanne Tudorica
may@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France
NewCap
Alexia Faure/Nicolas Merigeau
poxel@newcap.eu
+33 1 44 71 98 51

Source: Poxel SA

Released May 21, 2019